GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (LTS:0A5J) » Definitions » Capex-to-Operating-Income

Dermapharm Holding SE (LTS:0A5J) Capex-to-Operating-Income : 0.26 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dermapharm Holding SE Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Dermapharm Holding SE's Capital Expenditure for the three months ended in Dec. 2024 was €-11.88 Mil. Its Operating Income for the three months ended in Dec. 2024 was €45.66 Mil.

Hence, Dermapharm Holding SE's Capex-to-Operating-Income for the three months ended in Dec. 2024 was 0.26.


Dermapharm Holding SE Capex-to-Operating-Income Historical Data

The historical data trend for Dermapharm Holding SE's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Capex-to-Operating-Income Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.21 0.16 0.23 0.18

Dermapharm Holding SE Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.11 0.31 0.12 0.26

Competitive Comparison of Dermapharm Holding SE's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Capex-to-Operating-Income falls into.


;
;

Dermapharm Holding SE Capex-to-Operating-Income Calculation

Dermapharm Holding SE's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-38.237) / 214.732
=0.18

Dermapharm Holding SE's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-11.879) / 45.655
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (LTS:0A5J) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Dermapharm Holding SE Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.

Dermapharm Holding SE Headlines

No Headlines